| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Research and development | 262,506 | 224,134 | 151,752 | |
| General and administrative | 52,763 | 40,580 | 23,960 | |
| Total operating expenses | 315,269 | 264,714 | 175,712 | |
| Loss from operations | -315,269 | -264,714 | -175,712 | |
| Interest income | 22,083 | 22,404 | 20,411 | |
| Interest and other income (expense), net | - | -899 | - | |
| Interest expense | 11,428 | - | - | |
| Change in fair value of warrant liabilities and contingent earn-out shares | -592 | -4,578 | -1,269 | |
| Other income (expense), net | 0 | - | 282 | |
| Total non-operating income, net | 10,063 | 16,927 | 19,424 | |
| Loss before income taxes | -305,206 | -247,787 | -156,288 | |
| Net loss | -305,206 | -247,787 | -156,288 | |
| Unrealized gain on investments, net | 1,814 | - | 5,675 | |
| Comprehensive loss | -303,392 | - | -150,613 | |
| Net loss per share attributable to common stockholders, basic | -1.61 | -1.31 | -0.94 | |
| Net loss per share attributable to common stockholders, diluted | -1.61 | -1.31 | -0.94 | |
| Weighted average number of shares outstanding, diluted | 189,231,562 | 188,583,288 | 166,843,984 | |
| Weighted-average shares used to compute net loss per share attributable to common stockholders-basic | 189,231,562 | 188,583,288 | 166,843,984 | |
Revolution Medicines, Inc. (RVMD)
Revolution Medicines, Inc. (RVMD)